skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach to lowering prescription drug pricing, Grogan says.

 

 

 

 

 

The Trump Administration will be successful in finding solutions to high prescription drug pricing in part because it has enlisted individuals with biopharma industry experience to direct the development of policies, Office of Management and Budget Associate Director for Health Programs Joe Grogan told the Biopharma Congress in Washington, DC on Nov. 14.

 

 

Comparing the Trump Administration's approach to drug pricing with that in the Obama Administration, he predicted: "We're going to be more successful. We've had more people with more drug experience looking at it."

 

 

Grogan pointed to FDA Commissioner Scott Gottlieb as one example. Gottlieb's experience with the biopharma industry included extensive work as a consultant to companies and with a venture capital firm. He also served on drug company boards.

 

 

Although Grogan said he doesn't believe Gottlieb is intervening directly in drug pricing, "he's taking on regulatory inefficiencies that create unnatural barriers to competition."

 

 

FDA "should have an obligation to effect what Scott is doing, which is to figure out a way to make sure that taxpayers and consumers are not adversely hindered unnecessarily because [the agency] has not figured out, or they haven't paid much attention to, some quirk in the regulatory scheme that allows people to game the system," Grogan maintained. "He's willing to take on sacred cows. He's willing to shake things up and he's doing an outstanding job."

 

 

Grogan cited President Trump's selection of Alex Azar as HHS secretary as another example of the Administration's strategic approach to developing drug pricing solutions. Azar spent 10 years with Eli Lilly & Co. prior to his nomination. (Also see "HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority" - Pink Sheet, 13 Nov, 2017.)

 

 

In Azar, "he's chosen someone who understands how drug pricing works, how the [supply] channel works, how to mix things up, inefficiencies in how these programs work and inefficiencies in pricing that create bizarre distortions, where some people pay more than is fair and some people pay less than is fair."

 

 

Grogan himself also brings a track record with biopharma. He worked at Amgen Inc. for two years (June 2009 to November 2011) as director of global regulatory affairs and was head of government affairs at Gilead Sciences Inc.from November 2011 to March 2017.

 

 

Trump Administration vs. Obama's On Drug Pricing

On drug pricing, the Obama Administration relied on "more people with the insurance company view," Grogan said. "From the outside, it looked like they were not willing to take on some sacred cows because they didn't want to upset people on the [Affordable Care Act] side."

 

 

He also suggested Obama officials were too caught up in the ACA to devote substantial resources to drug pricing. "They spent so much time trying to make a flawed structure work. They may have said that drug pricing was a problem but to be frank, outside of the Part B demo they did not devote as much bandwidth as we're devoting to it."

 

 

The Medicare Part B demonstration, which was proposed by the Obama Administration in early 2016, would have revised the reimbursement formula for drugs and experimented with novel payment models. It was withdrawn in response to strong opposition from physicians and biopharma manufacturers. (Also see "CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does" - Pink Sheet, 16 Dec, 2016.)

 

 

"We're totally committed to" drug pricing reform, Grogan emphasized. "It is the number one issue for voters." The Administration's focus is on "pain in the pocketbook. When they go to the counter…what they have to pay out-of-pocket hits them and it matters. The Administration has made it clear that we are not going to just put things on auto-pilot. We're going to try and do what we can to find some relief."

 

 

"I wouldn't necessarily get tied up in whether there is an executive order," Grogan said. "This is not the end of our drug pricing efforts."

 

 

He stopped short of discussing any specific proposals in the works. However, he said "when we started having discussions, we were clear we shouldn't take anything off the table. Things that the Republican party or conservatives had normally rejected needed to be considered."

 

 

Grogan also said the Administration wants to take a hard look at how taxpayer money is supporting the drug industry through government programs. He explained President Trump's budget proposal that user fees fund 100% of FDA review activities grew out of that concern. (Also see "FDA Safety Initiatives Could Suffer Under Trump's Budget Proposal" - Pink Sheet, 23 May, 2017.)

 

 

"We're spending a ton of money we don't have every year and we have to look at the sacred cows and places that we don't want to, to find money," he maintained.

 

 

"The president made it very clear he was going to upset the apple cart and had issues with some of the conduct in the pharma industry. He wanted to spark a debate. … I think we could debate whether we should have a level of taxpayer support for the review process, but to be frank, taxpayers fund a ton for NIH, we fund a ton at CMS in Part D, we fund a ton at FDA. At some point, you've got to start asking questions."

 

 

Biosimilars Coding Rule Could Change, Based On Evidence

Grogan discussed two recent Medicare rules that illustrate the Administration's approach to dealing with high drug costs. Neither imposes pricing controls on manufacturers. The first reverses an Obama-era policy on Medicare payments for biosimilars, in effect allowing biosimilar marketers more leeway on pricing to help spur development in the space. (Also see "Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'" - Pink Sheet, 3 Nov, 2017.)

 

 

"You're starting to see the Administration's philosophy around drug pricing generally in the health care space," he said. "We're very focused on competition and choice for individuals and competition for payers being able to choose various products. That's the lens through which we're looking at this."

 

 

He acknowledged arguments that the rule, which allows each biosimilar its own reimbursement code and payment, may lead to higher costs. If evidence supports that view, the Administration may rethink the decision, Grogan said.

 

 

"If ultimately it's going to show it's going to cost taxpayers a bunch of money and that this is really an easy [market] to get into, then ultimately we'll revise the decision."

 

 

Medicare Rule Cutting 340B Payments Shows 'We're Not Wimps'

The other rule will significantly reduce Medicare reimbursement to hospitals for drugs subject to discounts under the 340B program. (Also see "Medicare Lowers Payments For 340B Drugs: Promising Sign For Further Reform?" - Pink Sheet, 2 Nov, 2017.)

 

 

The rule "is viewed as an opportunity to provide relief to the customers who are sometimes paying deductibles based on the [list] price, which is not what the hospital is paying," he explained.

 

 

"The Administration felt we had to make a move here on 340B," Grogan emphasized. "It's an incredibly flawed program in how it's operating. It grew far beyond its intent and it's unconnected with its stated intent in many instances."

 

 

Although there have been efforts in Congress to reform 340B, "it's an incredibly difficult program to address legislatively," he said. "The Administration cannot just sit back indefinitely and not take action here. We've got to shake some things up and provide some relief to people."

 

 

Hospitals are actively fighting the rule and have filed a lawsuit against the department. "We took a ton of heat for that proposal," Grogan acknowledged. But "I think what everybody should take away from it is we're not wimps."

 

 

"We're not wimps on 340B and we're not wimps generally speaking," he continued. "We've lost a secretary" with the recent departure of HHS Secretary Tom Price, "and we've dealt with three different [ACA] repeal and replace bills. You've got a team that understands the regulatory process … and they're going to move aggressively on regulations." Price resigned in late September over complaints that he wasted taxpayer money on expensive transportation. (Also see "HHS Leadership Upheaval Could Delay Initiatives Impacting Biopharma" - Pink Sheet, 29 Sep, 2017.)

 

 

Status Of Executive Order

Grogan suggested that an executive order on drug pricing may not materialize. The possibility of an executive order has generated widespread speculation among stakeholders, and a draft version of a biopharma-friendly order made the rounds in policy circles last July. (Also see "Trump Exec Order On Drug Costs: Seeking To Balance Access, Innovation" - Pink Sheet, 23 Jun, 2017.)

 

 

"I wouldn't necessarily get tied up in whether there is an executive order, [or] a speech, how the president messages," he said. "The idea of a drug pricing executive order has been discussed. … but I wouldn't get bolluxed up on the vehicle. We are working very hard on this and this is not the end of our drug pricing efforts."

Read also

  • In Vivo: strategic insights for life sciences decision-maker...

    Pharma News and Healthcare Business Insights

    <p><span>Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare &amp; biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.</span></p>

  • Pink Sheet: global policy and regulatory coverage

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: